ES2550389T3 - Producto de CD6 para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados - Google Patents

Producto de CD6 para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados Download PDF

Info

Publication number
ES2550389T3
ES2550389T3 ES08750412.2T ES08750412T ES2550389T3 ES 2550389 T3 ES2550389 T3 ES 2550389T3 ES 08750412 T ES08750412 T ES 08750412T ES 2550389 T3 ES2550389 T3 ES 2550389T3
Authority
ES
Spain
Prior art keywords
rscd6
lps
product
gram
inflammatory processes
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES08750412.2T
Other languages
English (en)
Spanish (es)
Inventor
Maria Rosa SARRIAS FORNÉS
Francisco Lozano Soto
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Universitat de Barcelona UB
Original Assignee
Universitat de Barcelona UB
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universitat de Barcelona UB filed Critical Universitat de Barcelona UB
Application granted granted Critical
Publication of ES2550389T3 publication Critical patent/ES2550389T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/177—Receptors; Cell surface antigens; Cell surface determinants
    • A61K38/1774—Immunoglobulin superfamily (e.g. CD2, CD4, CD8, ICAM molecules, B7 molecules, Fc-receptors, MHC-molecules)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Diabetes (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
ES08750412.2T 2007-03-28 2008-03-27 Producto de CD6 para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados Active ES2550389T3 (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
ES200700893 2007-03-28
ES200700893 2007-03-28
PCT/ES2008/000177 WO2008119851A1 (es) 2007-03-28 2008-03-27 Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados

Publications (1)

Publication Number Publication Date
ES2550389T3 true ES2550389T3 (es) 2015-11-06

Family

ID=39807834

Family Applications (1)

Application Number Title Priority Date Filing Date
ES08750412.2T Active ES2550389T3 (es) 2007-03-28 2008-03-27 Producto de CD6 para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados

Country Status (6)

Country Link
US (1) US8691752B2 (https=)
EP (1) EP2143436B1 (https=)
JP (1) JP5583575B2 (https=)
CA (1) CA2681828A1 (https=)
ES (1) ES2550389T3 (https=)
WO (1) WO2008119851A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2008119851A1 (es) * 2007-03-28 2008-10-09 Universidad De Barcelona Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
JP2014516046A (ja) * 2011-05-26 2014-07-07 フンダシオ・クリニック・ペル・ア・ラ・レセルカ・ビオメディカ がん若しくは腫瘍の治療用の又はアジュバントとして使用される可溶性タンパク質ｃｄ５又はｃｄ６
JP2019535834A (ja) 2016-11-18 2019-12-12 ユニベルシタ デ バルセロナ 感染症及び関連炎症プロセスの処置のためのｃｄ６及びイミペネムの併用療法
ES2953362T3 (es) 2018-03-13 2023-11-10 Sepsia Therapeutics S L Péptidos de unión bacteriana para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6315999B1 (en) * 1989-08-10 2001-11-13 Solvay, S.A. Pharmaceutical product for the treatment of sepsis
WO1993019772A1 (en) 1992-04-06 1993-10-14 North Shore University Hospital Research Corporation A novel therapy for treating sepsis using a soluble form of recombinant cd14 myelomonocytic antigen
CA2175247A1 (en) 1993-11-02 1995-05-11 Barton F. Haynes Cd6 ligand
US6290948B1 (en) * 1996-05-14 2001-09-18 Smithkline Beecham Corporation Method of treating sepsis and ARDS using chamohine beta-10
CA2268085A1 (en) * 1996-10-22 1998-04-30 Go Wakabayashi Sepsis remedy comprising anti-il-8 antibody as active ingredient
US6172220B1 (en) * 1997-01-21 2001-01-09 Board Of Regents Of University Of Nebraska Isolated algal lipopolysaccharides and use of same to inhibit endotoxin-initiated sepsis
WO2000023101A1 (en) * 1998-10-22 2000-04-27 Eli Lilly And Company Methods for treating sepsis
US20030114377A1 (en) * 1998-11-18 2003-06-19 Kirkland Theo N. Inhibition therapy for septic shock with mutant CD14
US6673346B1 (en) * 1999-08-31 2004-01-06 The Regents Of The University Of Michigan Compositions and methods for the treatment of sepsis
US20020006915A1 (en) 2000-02-15 2002-01-17 Mack Strong Vivian E. Use of COX-2 inhibitors to treat sepsis, complications thereof, and EP receptor modulation
EP1278749B1 (en) * 2000-04-25 2005-01-26 Bristol-Myers Squibb Company USE OF 5-THIO-, SULFINYL- AND SULFONYLPYRAZOLO 3,4-b]-PYRIDINES AS CYCLIN DEPENDENT KINASE INHIBITORS
ES2334773T3 (es) * 2001-05-16 2010-03-16 Yeda Research And Development Co. Ltd. Uso de inhibidores de il-18 para el tratamiento o prevencion de la sepsis.
US6729735B2 (en) 2001-06-28 2004-05-04 Plx, Inc. Lateral transfer retroreflector assembly and method of assembling the same
WO2005019258A2 (en) * 2003-08-11 2005-03-03 Genentech, Inc. Compositions and methods for the treatment of immune related diseases
GB0426146D0 (en) 2004-11-29 2004-12-29 Bioxell Spa Therapeutic peptides and method
WO2008119851A1 (es) * 2007-03-28 2008-10-09 Universidad De Barcelona Producto proteico para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
ES2336752B1 (es) * 2008-06-20 2011-05-11 Hospital Clinic I Provincial De Barcelona Composiciones farmaceuticas de cd5.

Also Published As

Publication number Publication date
JP2010522728A (ja) 2010-07-08
US20100105622A1 (en) 2010-04-29
CA2681828A1 (en) 2008-10-09
JP5583575B2 (ja) 2014-09-03
EP2143436A1 (en) 2010-01-13
US8691752B2 (en) 2014-04-08
WO2008119851A1 (es) 2008-10-09
EP2143436A4 (en) 2013-11-20
EP2143436B1 (en) 2015-07-29

Similar Documents

Publication Publication Date Title
Gauchotte et al. SARS-Cov-2 fulminant myocarditis: an autopsy and histopathological case study
Aihara et al. Motility and chemotaxis mediate the preferential colonization of gastric injury sites by Helicobacter pylori
ES2550389T3 (es) Producto de CD6 para el tratamiento de enfermedades infecciosas y procesos inflamatorios relacionados
Mishra et al. Galectin-3 functions as an alarmin: pathogenic role for sepsis development in murine respiratory tularemia
CO6180445A2 (es) Anticuerpos agonistas anti notch3 y su uso en el tratamiento de las enfermedades relacionadas con el gen notch3
Rui et al. Urinary trypsin inhibitor attenuates seawater-induced acute lung injury by influencing the activities of nuclear factor-ĸB and its related inflammatory mediators
Achouiti et al. Receptor for advanced glycation end products (RAGE) serves a protective role during Klebsiella pneumoniae-induced pneumonia
Fukushi et al. Laninamivir octanoate and artificial surfactant combination therapy significantly increases survival of mice infected with lethal influenza H1N1 virus
Scur et al. Alveolar macrophage metabolic programming via a C-type lectin receptor protects against lipo-toxicity and cell death
Cheemarla et al. Neutrophils regulate the lung inflammatory response via γδ T cell infiltration in an experimental mouse model of human metapneumovirus infection
Ge et al. Complement and complement regulatory proteins are upregulated in lungs of COVID-19 patients
Porte et al. Regulation of inflammation and protection against invasive pneumococcal infection by the long pentraxin PTX3
CN102854176A (zh) 一种tmem16a钙激活氯离子通道抑制剂的筛选方法
Liao et al. Acute respiratory distress syndrome manifested by leptospirosis successfully teated by extracorporeal membrane oxygenation (ECMO)
FR2973109B1 (fr) Methode cytologique utilisant l'autofluorescence des globules blancs pour le diagnostic precoce et le suivi des infections
RU2008123442A (ru) Способ определения ранних лабораторных маркеров генерализации инфекции у больных острым миелобластным лейкозом при нейтропении
WO2019025639A1 (en) DIAGNOSIS AND STRATIFICATION OF RISKS OF FUNGAL INFECTION
Liu et al. Prognostic significance of serum antioxidant parameters in immunocompetent patients with cryptococcal meningitis
Rahimi et al. A sudden paediatric death due to hand, foot and mouth disease: the importance of vigilance
Touyz Periodontitis contributes to initiation, progress and aggravation of septic shock; a feasible hypothesis
Sutyak Noll et al. Elucidation of the molecular mechanisms of action of the natural antimicrobial peptide subtilosin against the bacterial vaginosis-associated pathogen Gardnerella vaginalis
Vega-Carrascal et al. Expression Of T-cell Immunoglobulin And Mucin-domain-containing Molecule-1 (TIM-1) And TIM-3 Is Upregulated In Human Bronchial Epithelial Cells In Cystic Fibrosis
Konyak et al. Scrub typhus associated acute kidney injury in a 33-year-old male
Heintze A neutrophil motility assay for early diagnosis of sepsis
Fretz et al. Chronic lymphocytic leukaemia, dyspnoea and “tree-in-bud” sign on chest CT scan